Comments
AstraZeneca Plc plans to start early and mid-stage clinical trials of its Covid-19 vaccine candidate in China this year, a senior executive said on Friday, as it prepares a global rollout of the vaccine.
The vaccine candidate is already in the final stage of clinical trials in other countries, and AstraZeneca and its partner on the project, the University of Oxford, expect data from the late-stage trials this year.
If successful, they will file for emergency approvals in as many countries as possible at the same time, its CEO, Pascal Soriot, said this week.
Also read:
In China, the company has a deal with Shenzhen Kangtai Biological Products to manufacture the vaccine in the country.
Under the agreement, Shenzhen Kangtai, one of China's top vaccine makers, will ensure it has annual production capacity of at least 100 million doses of the experimental shot AZD1222 by the end of this year.
Also read:
The vaccine may be approved for use in China by mid-2021 after gathering safety data from Phase 1 and Phase 2 trials in China and efficacy data from Phase 3 trials overseas, Leon Wang, head of AstraZeneca's China operation told Reuters.
Wang said its trials in China would use vaccines manufactured by local partner Shenzhen Kangtai.
Also read:
Related Stories
India-made Covid-19 vaccine could be launched as early as February: Scientist
Bharat Biotech's COVAXIN, being developed with Indian Council of Medical Research, was earlier expected to be launched in the second quarter of next yearAlso read:
Related Stories
Covid-19 vaccine nationalism may cost global economy up to $1.2 trillion a year: Study
Countries pedalling ‘vaccine nationalism’ will likely hoard vaccines by striking a deal directly with pharma companies, the study saysAlso read:
Related Stories
Oxford Covid-19 vaccine triggers immune responses in elderly: Report
Since carlier studies had said old people were most vulnerable to coronavirus, health administration needs to be cautioned that positive immunogenicity tests don’t mean vaccine is safe, effective for old people, says report
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.